Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073489 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study of Chronic Lymphocytic Leukemia, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 15
- Study locations
NCT00073489 is a Phase 2 study of Chronic Lymphocytic Leukemia that has completed, run by Astellas Pharma. The registered enrollment target is 23 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower). The trial reports 15 study locations across 12 states.
The verdict
NCT00073489, a Phase 2 study of Chronic Lymphocytic Leukemia, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 15
- Study locations
Study Summary
The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.
Conditions Studied
Interventions
- DRUG OSI-461
Study Locations (15)
Texas
- Southwest Regional Cancer Center - Austin
- Hematology Oncology Associates of South Texas - San Antonio
- Tyler Cancer Center - Tyler
Florida
- Florida Oncology Associates - Jacksonville
- Ocala Oncology Center - Ocala
Arizona
- Arizona Hematology & Oncology Associates - Phoenix
Colorado
- Rocky Mountain Cancer Centers - Aurora
Iowa
- Iowa Oncology Associates - Cedar Rapids
Missouri
- Oncology/Hematology Associates of Kansas City - Kansas City
North Carolina
- Piedmont Hem Onc Assoc, P.A. - Winston-Salem
Ohio
- Dayton Oncology/Hematology Consultants - Dayton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2001-05 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073489
The ClinicalTrials.gov registry entry for NCT00073489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (87% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which OSI-461 is the first listed.
NCT00073489 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Texas, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00073489 about?
NCT00073489 is a clinical study titled "A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)". The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.
What is the current status of trial NCT00073489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2001-05. Estimated completion is 2003-12.
What conditions does trial NCT00073489 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT00073489?
The interventions under investigation include: OSI-461 (DRUG).
Who is sponsoring clinical trial NCT00073489?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073489 being conducted?
This trial has 15 study locations across Arizona, Colorado, Florida, Iowa, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RECRUITING · Phase 2
-
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RECRUITING · Phase 2
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.